// App-Quantinova.ai

: The Comparative Pharmacokinetic (PK) Profiles of Two Extended Half‐life (EHL) Factor VIII Concentrates [rFVIII‐Fc (Eloctate) and rAHF‐FL‐PEG (Adynovate)] in Adolescent Boys with Hemophilia A: Is there a Difference?

Researchers

Presenter

  • M. Carcao

Principal Investigators

  • P. Chelle

  • E. Clarke

  • L. Kim

  • L. Tiseo

  • M. Morfini

  • M. Rand

  • T. Hossain

  • C. Brown

  • A. Edginton

  • D. Lillicrap

  • A. Iorio

  • V. Blanchette

Medical Centers

  • Hospital for Sick Children, University of Toronto, Division of Pediatric Hematology/Oncology, Toronto, Canada

  • The Hospital for Sick Children, Child Health Evaluative Sciences, Research Institute, Toronto, Canada

  • University of Waterloo, School of Pharmacy, Kitchener, Canada

  • Hospital for Sick Children, Toronto, ON, Canada

  • Italian Association of Haemophilia Centres, Florence, Italy

  • Hospital for Sick Children, Translational Medicine, Research Institute, Toronto, Canada

  • University of Toronto, Department of Laboratory Medicine & Pathobiology, Biochemistry, and Pediatrics, Toronto, Canada

  • Queen's University, Pathology & Molecular Medicine, Kingston, Canada

  • McMaster University, Department of Health Research Methods, Evidence and Impact, Department of Medicine, Hamilton, Canada

Locations

  • Canada

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • FVIII

  • Eloctate

  • rFVIII

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved